Eli Lilly (LLY): FY24 Q3 earnings call, Oct 30, 2024
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2024 earnings call (FY24 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Vial”; 5 quoted, at least 25 words apart.
…wholesale channel and LillyDirect Pharmacy Solutions. The launch of a single-dose Zepbound vials in the U.S. exclusively through LillyDirect's self-pay channel further expanded supply and…
…employer opt-ins. We are in the early days of launching single-dose Zepbound vials in the U.S. exclusively through LillyDirect. 2.5 milligram and 5-milligram single-dose vials…
…ARIA-E. In this trial, we tested a modified titration, which shifted one vial of donanemab from the first infusion to the third, as shown on…
…I'm trying to think out loud, could the launch of cash-pay single vial option via LillyDirect have impacted channels' interest in filling out their inventory…
…no. We didn't change our terms, and I don't think we've seen any change in retail stocking of the auto-injector because the vials are filled.
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2024-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2024-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP